肌醇治疗多囊卵巢综合征女性无排卵:随机试验的荟萃分析
该系统评价与荟萃分析纳入10项随机对照试验,比较肌醇与安慰剂或其他促排卵药物对多囊卵巢综合征患者的作用。与安慰剂相比,肌醇显著改善排卵率(RR 2.3;95%CI 1.1-4.7;I²=75%)并增加月经周期频率(RR 6.8;95%CI 2.8-16.6;I²=0%)。临床妊娠率仅单项研究报告,与安慰剂比较RR 3.3(95%CI 0.4-27.1),与二甲双胍比较RR 1.5(95%CI 0.7-3.1);无研究评估活产和流产率。
要点
- 与安慰剂相比,肌醇显著改善排卵率(RR 2.3;95%CI 1.1-4.7;I²=75%)。
- 与安慰剂相比,肌醇显著增加月经周期频率(RR 6.8;95%CI 2.8-16.6;I²=0%)。
- 无研究评估活产和流产率,证据不足以支持妊娠结局。
核心结论
- 肌醇似乎可调节多囊卵巢综合征患者的月经周期、改善排卵并诱导代谢改变,但缺乏妊娠、流产或活产的证据。
- 有必要进一步设计良好的多中心试验以提供肌醇获益的可靠证据。
研究设计与样本
- 系统评价与荟萃分析,纳入10项随机对照试验。
- 检索MEDLINE、EMBASE、Cochrane及ISI会议论文集、RCT注册库与Meta注册库、WHO试验检索门户。
- 纳入比较肌醇与安慰剂或其他促排卵药物的研究,评估偏倚风险,采用随机效应模型合并,报告相对风险或标准化均数差。
- 共362名女性使用肌醇(257名使用肌醇myo-inositol;105名使用D-手性肌醇di-chiro-inositol),179名使用安慰剂,60名使用二甲双胍。
主要发现
- 与安慰剂相比,肌醇显著改善排卵率(RR 2.3;95%CI 1.1-4.7;I²=75%)。
- 与安慰剂相比,肌醇显著增加月经周期频率(RR 6.8;95%CI 2.8-16.6;I²=0%)。
- 一项研究报告肌醇与安慰剂比较的临床妊娠率(RR 3.3;95%CI 0.4-27.1),一项研究与二甲双胍比较(RR 1.5;95%CI 0.7-3.1)。
- 无研究评估活产和流产率。
临床怎么用
- 原文未据此给出推荐。
局限性
- 排卵率分析异质性I²=75%。
- 仅一项研究报告肌醇与安慰剂比较的临床妊娠率,其95%CI 0.4-27.1较宽。
- 无研究评估活产和流产率。
- 作者认为有必要进一步设计良好的多中心试验以提供肌醇获益的可靠证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Polycystic ovary syndrome is a common cause of anovulation and infertility, and a risk factor for development of metabolic syndrome and endometrial cancer. Systematic review and meta-analysis of randomised controlled trials (RCT) that evaluated the effects of inositol as an ovulation induction agent. We searched MEDLINE, EMBASE, Cochrane and ISI conference proceedings, Register and Meta-register for RCT and WHO trials' search portal. We included studies that compared inositol with placebo or other ovulation induction agents. Quality of studies was assessed for risk of bias. Results were pooled using random effects meta-analysis and findings were reported as relative risk or standardised mean differences. We included ten randomised trials. A total of 362 women were on inositol (257 on myo-inositol; 105 on di-chiro-inositol), 179 were on placebo and 60 were on metformin. Inositol was associated with significantly improved ovulation rate (RR 2.3; 95% CI 1.1-4.7; I2 = 75%) and increased frequency of menstrual cycles (RR 6.8; 95% CI 2.8-16.6; I2 = 0%) compared with placebo. One study reported on clinical pregnancy rate with inositol compared with placebo (RR 3.3; 95% CI 0.4-27.1), and one study compared with metformin (RR 1.5; 95% CI 0.7-3.1). No studies evaluated live birth and miscarriage rates. Inositol appears to regulate menstrual cycles, improve ovulation and induce metabolic changes in polycystic ovary syndrome; however, evidence is lacking for pregnancy, miscarriage or live birth. A further, well-designed multicentre trial to address this issue to provide robust evidence of benefit is warranted. TWEETABLE ABSTRACT: Inositols improve menstrual cycles, ovulation and metabolic changes in polycystic ovary syndrome.
引用
- Pundir J, Psaroudakis D, Savnur P, et al. Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials. BJOG. 2017. PMID: 28544572. doi:10.1111/1471-0528.14754
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。